Voxel S.A. - Asset Resilience Ratio
Voxel S.A. (VOX) has an Asset Resilience Ratio of 0.32% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VOX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2023)
This chart shows how Voxel S.A.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VOX total assets.
Liquid Assets Composition Over Time
This chart breaks down Voxel S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Voxel S.A. to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł2.19 Million | 0.32% |
| Total Liquid Assets | zł2.19 Million | 0.32% |
Asset Resilience Insights
- Limited Liquidity: Voxel S.A. maintains only 0.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Voxel S.A. Industry Peers by Asset Resilience Ratio
Compare Voxel S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 13.42% |
|
Check-Cap Ltd
F:7CC |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for Voxel S.A. (2018–2023)
The table below shows the annual Asset Resilience Ratio data for Voxel S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 1.18% | zł6.23 Million ≈ $1.71 Million |
zł529.03 Million ≈ $145.60 Million |
-0.10pp |
| 2022-12-31 | 1.28% | zł5.99 Million ≈ $1.65 Million |
zł467.35 Million ≈ $128.62 Million |
+1.16pp |
| 2021-12-31 | 0.12% | zł615.80K ≈ $169.48K |
zł495.05 Million ≈ $136.24 Million |
-0.39pp |
| 2020-12-31 | 0.51% | zł2.25 Million ≈ $620.42K |
zł438.23 Million ≈ $120.61 Million |
-4.25pp |
| 2019-12-31 | 4.76% | zł16.08 Million ≈ $4.43 Million |
zł337.91 Million ≈ $93.00 Million |
-0.28pp |
| 2018-12-31 | 5.04% | zł14.22 Million ≈ $3.91 Million |
zł282.33 Million ≈ $77.70 Million |
-- |
About Voxel S.A.
Voxel S.A. provides medical services in Poland. The company offers imaging diagnostics services, including reimbursed, commercial, and private patient examinations; teleradiology services; and clinical/pharmaceutical trials. It is also involved in the sale of radiopharmaceuticals, and the leasing of land. Voxel S.A. was incorporated in 2005 and is headquartered in Kraków, Poland.